Evgen Pharma (GB:TCF) has released an update.
TheraCryf plc, a company specializing in oncology and neuropsychiatry, is set to host a Research and Development Day on 13 June 2024, where it will discuss its clinical and preclinical programs, market potential, and strategic outlook. The event, welcoming both virtual and in-person attendance, will feature updates on TheraCryf’s recent Chronos acquisition, its glioblastoma treatments, and neuropsychiatry research efforts. Interested parties, including sell-side analysts and current or potential shareholders, are invited to register for the event.
For further insights into GB:TCF stock, check out TipRanks’ Stock Analysis page.
